Results 111 to 120 of about 24,275 (247)

The emerging role of the Hippo signaling pathway in interorgan crosstalk

The FEBS Journal, EarlyView.
Hippo signaling functions as a central hub of interorgan communication. Systemic cues from the gut, adipose tissue, and skeletal muscle—including hormones, metabolites, and microbial signals—regulate YAP/TAZ activity in a tissue‐ and context‐dependent manner.
Gahyeon Song, Chaerin Lee, Eek‐hoon Jho   +2 more
wiley   +1 more source

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis

Frontiers in Pharmacology, 2019
ObjectiveThe aim of this study was to investigate whether the nuclear receptor farnesoid X receptor (FXR) could regulate FNDC5/Irisin expression and the role of Irisin in hyperlipidemia and atherosclerosis in ApoE-/- mice.Methods and ResultsWe treated ...
Hong Li, Hong Li, Jing Shen, Jing Shen, Tong Wu, Tong Wu, Jiangying Kuang, Jiangying Kuang, Qinhui Liu, Shihai Cheng, Shihai Cheng, Shiyun Pu, Shiyun Pu, Lei Chen, Lei Chen, Rui Li, Rui Li, Yanping Li, Yanping Li, Min Zou, Zhiyong Zhang, Wei Jiang, Aijuan Qu, Jinhan He, Jinhan He   +24 more
doaj   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, EarlyView.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

Hepatology Research, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida   +44 more
wiley   +1 more source

Bile acids and nonalcoholic fatty liver disease: An intriguing relationship [PDF]

, 2016
Non-alcoholic fatty liver disease (NAFLD) stands nowadays as a leading cause of progressive impairment of liver function. The role of bile acids in the modulation of hepatic lipid metabolism is interesting and controversial; previous evidence showed an ...
Gabbi, Lonardo, Nagahashi, Watanabe
core   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Allosteric modulation of the farnesoid X receptor by a small molecule

Scientific Reports, 2018
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders.
Matthias Gabler, Jan Kramer, Jurema Schmidt, Julius Pollinger, Julia Weber, Astrid Kaiser, Frank Löhr, Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk   +9 more
doaj   +1 more source

Effects of Weight Loss Interventions on Gut Microbiota‐Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta‐Analysis

Obesity Reviews, EarlyView.
ABSTRACT Background Gut microbiota‐derived metabolites are emerging as potential mediators between obesity and cardiometabolic conditions. While weight loss interventions modify microbiota composition, their effects on systemic microbial metabolites remain unclear.
Fernando Q. Iorra, Leonardo André Swarowsky Loebens, Andrea Auler, Eduarda Caroline Tasso Nascimento, Beatriz D. Schaan, Patrícia Martins Bock   +5 more
wiley   +1 more source

Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice [PDF]

, 2017
The nuclear bile acid receptor FXR (farnesoid-X-receptor) has recently been implicated in the pathophysiology of non-alcoholic fatty liver disease because selective FXR-agonists improve glucose and lipid metabolism in rodent models of obesity.
Geier, Andreas, Martin, Ina V., Mertens, Joachim C., Minkenberg, Alexander, Mullhaupt, Beat, Schmitt, Johannes, Stieger, Bruno   +6 more
core  

Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis. [PDF]

, 2013
Caveolin-1 (Cav1) is a scaffold protein and pathogen receptor in the mucosa of the gastrointestinal tract. Chronic infection of gastric epithelial cells by Helicobacter pylori (H. pylori) is a major risk factor for human gastric cancer (GC) where Cav1 is
A Bist, A Lee, A Muller, AB Rogers, AS Day, B Razani, C Pelz, C Wunder, CG Hansen, CH Kuo, CH Lai, CH Lai, Christoph Röcken, Claus Schäfer, CM Rosenberger, D Engel, D Forman, D Makola, DW Zaas, E Burgermeister, E Burgermeister, E Burgermeister, E Prade, E Touati, E Touati, Elke Burgermeister, F Lian, F Sommer, FA Medina, FA Medina, FA Medina, Florian Anderl, FS Machado, G Li, G Soong, Gang Yuan, I Mercier, I Regel, IC Arnold, IC Arnold, IC Arnold, IM Toller, Ivana Hitkova, J Li, J Millan, JC Atherton, JE Crabtree, JG Fox, JH Chidlow Jr, JP Boettcher, JS Low, JW Yam, K Ohnuma, K Simons, K Yuan, KM Bourzac, LJ Thompson, M Beigier-Bompadre, M Gadjeva, M Hatakeyama, M Kurayoshi, M Mohammadi, M Yamaga, Markus Gerhard, Matthias P. A. Ebert, MF Dixon, MJ Zhang, ML Hutton, MM D'Elios, MP Ebert, MP Ebert, MR Amieva, NE van Doorn, OA Senkovich, P Gargalovic, P Kundu, P Lajoie, PU Le, R Palovuori, R Rad, R Tsutsumi, Roger Vogelmann, Roland M. Schmid, S Li, S Moese, S Thomas, Simone Reu, Steven R. Blanke, T Kawazoe, T Tomassian, TH Tsai, Thomas Kirchner, TI Jeon, TM Williams, TM Williams, TY Kim, VM Pietiainen, W Schraw, X Cao, X Xing, Y Churin, Y Mitsuno, Y Yamaoka, YC Liao   +103 more
core   +4 more sources